Drugs currently approved for treatment of idiopathic pulmonary fibrosis (IPF) (pirfenidone or nintedanib) slow the decline of FVC (forced vital capacity) over time. Nonetheless, there is still a medical need for effective and better tolerated therapies. Pamrevlumab (FG-3019) is a human monoclonal antibody against connective tissue growth factor (CTGF) that is well tolerated by IPF patients. Preliminary data from an open-label Phase 2 trial in IPF suggest that pamrevlumab may have stabilized or improved FVC as well as lung fibrosis assessed by quantitative HRCT (qHRCT) in about one third of patients. Based on these positive findings, PRAISE was initiated. 103 patients with IPF per current guidelines, with FVC ≥55% predicted, DLCO ≥30% predicted and between 10% and 50% lung fibrosis by HRCT, were randomized to receive 16 doses of pamrevlumab (30 mg/kg IV q3w) or placebo for 48 weeks. Two additional cohorts on stable dosing with pirfenidone (n=36) or nintedanib (n=21) were also enrolled for 24 weeks. Patients were assessed for FVC, patient reported outcomes and biomarkers every 12 weeks. Lung fibrosis was assessed by qHRCT centralized reading every 24 weeks. Safety was assessed continuously throughout the study. At baseline, randomized patients were male (71.9%), white (88.8%) and former smoker (64.4%). Mean age was 68.3 years, median % predicted FVC and DLCO were 70.3% and 51.5% respectively and the median GAP score was 4. Last enrolled subject will complete participation in June 2017, at which time data will be unblinded. Safety and efficacy results of pamrevlumab in monotherapy and in combination with current IPF standard of care will be presented.